YIYuishin Izumi

Yuishin Izumi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuishin Izumi has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Akira Ohta

    Department of Fundamental Cell Technology, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan

    1 shared publication
  • Akira Tamaoka

    Department of Neurology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan

    1 shared publication
  • Akira Watanabe

    Medical Innovation Center (MIC), Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan

    1 shared publication
  • Akito Tanaka

    Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan

    1 shared publication
  • Akitsu Hotta

    Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan

    1 shared publication
  • Dai Watanabe

    Department of Biological Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan

    1 shared publication

Latest Publications

  • The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis

    by Keiko Imamura, Yuishin Izumi, Akira Watanabe, Kayoko Tsukita, Knut Woltjen, Takuya Yamamoto, Akitsu Hotta, Takayuki Kondo, Shiho Kitaoka, Akira Ohta, et al.

    Amyotrophic lateral sclerosis (ALS), a fatal disease causing progressive loss of motor neurons, still has no effective treatment. We developed a phenotypic screen to repurpose existing drugs using ALS motor neuron survival as readout. Motor neurons were generated from induced pluripotent stem cells (iPSCs) derived from an ALS patient with a mutation in superoxide dismutase 1 (SOD1). Results of the screen showed that more than half of the hits targeted the Src/c-Abl signaling pathway. Src/c-Abl inhibitors increased survival of ALS iPSC-derived motor neurons in vitro. Knockdown of Src or c-Abl with small interfering RNAs (siRNAs) also rescued ALS motor neuron degeneration. One of the hits, bosutinib, boosted autophagy, reduced the amount of misfolded mutant SOD1 protein, and attenuated altered expression of mitochondrial genes. Bosutinib also increased survival in vitro of ALS iPSC-derived motor neurons from patients with sporadic ALS or other forms of familial ALS caused by mutations in TAR DNA binding protein (TDP-43) or repeat expansions in C9orf72. Furthermore, bosutinib treatment modestly extended survival of a mouse model of ALS with an SOD1 mutation, suggesting that Src/c-Abl may be a potentially useful target for developing new drugs to treat ALS.